Danaher Diagnostics — Operating profit increased by 20.0% to $665.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.1%, from $615.00M to $665.00M. Over 3 years (FY 2021 to FY 2024), Diagnostics — Operating profit shows an upward trend with a 4.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved operational efficiency, better pricing power, or higher sales volume within the diagnostics portfolio, while a decrease may signal rising costs, competitive pricing pressure, or declining demand for diagnostic products.
This metric represents the operating income generated by the Diagnostics business segment, calculated as segment revenue...
Comparable to segment-level operating income reported by diversified life science and medical technology peers, though variations exist based on how companies allocate corporate overhead and shared R&D costs.
dhr_segment_diagnostics_operating_profit| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $649.00M | $145.00M | $893.00M | $886.00M | $800.00M | $761.00M | $989.00M | $677.00M | $424.00M | $539.00M | $766.00M | $830.00M | $556.00M | $615.00M | $624.00M | $718.00M | $554.00M | $665.00M |
| QoQ Change | — | -77.7% | +515.9% | -0.8% | -9.7% | -4.9% | +30.0% | -31.5% | -37.4% | +27.1% | +42.1% | +8.4% | -33.0% | +10.6% | +1.5% | +15.1% | -22.8% | +20.0% |
| YoY Change | — | — | — | — | +23.3% | +424.8% | +10.8% | -23.6% | -47.0% | -29.2% | -22.5% | +22.6% | +31.1% | +14.1% | -18.5% | -13.5% | -0.4% | +8.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.